MRTX 1133
Alternative Names: MRTX-1133Latest Information Update: 25 Jan 2024
At a glance
- Originator Array BioPharma; Mirati Therapeutics
- Developer Mirati Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- Preclinical Cancer; Multiple myeloma
Most Recent Events
- 23 Jan 2024 Mirati Therapeutics has been acquired by Bristol-Myers Squibb
- 09 Dec 2023 Preclinical trials in Multiple myeloma in USA (unspecified route) (Prior to December 2023)
- 09 Dec 2023 Pharmacodynamic data from preclinical studies in Multiple myeloma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)